2 billion large varieties!

On June 16, the official website of NMPA showed that Shanghai Shanghai Shanghai Pharmaceutical Xinya's lansoprazole for injection passed the consistency evaluation application, becoming the fourth over-evaluated enterprise of this variety and won the fifth batch of centralized procurement tickets
.

Lansoprazole is a new type of proton pump inhibitor (PPI) developed by Takeda, Japan.
Lansoprazole for injection can be used for duodenal ulcers with bleeding and gastric ulcers with bleeding that are not suitable for oral therapy.
, Treatment of diseases such as acute stress ulcer and acute gastric mucosal disease
.

According to data from Menet.
com, in 2020, the sales of terminal lansoprazole injections in China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will exceed 2 billion yuan.
Luoxin Pharmaceutical, Osay Kang and Yuekang pharmaceuticals ranked the top three in market share
.

Sales of terminal lansoprazole injections in public medical institutions in China (unit: ten thousand yuan)

Source: Mi Nei.
com, China's public medical institutions terminal competition pattern

Previously reviewed companies for Lansoprazole for injection

Source: Mi Nei Net Consistency Evaluation Database

Lansoprazole injection has been included in the fifth batch of centralized procurement, and the bid will be opened on June 23.
Shanghai Shangyao Xinya successfully passed the evaluation before the bid opening
.

Data source: Mi Neiwang database